 |
|
Intraductal Papillary Mucinous Tumors of the Pancreas Comprise 2 Clinical Subtypes
Differences in Clinical Characteristics and Surgical Management
Masao Kobari, MD;
Shinn-ichi Egawa, MD;
Kazuhiko Shibuya, MD;
Hiromune Shimamura, MD;
Makoto Sunamura, MD;
Kazunori Takeda, MD;
Seiki Matsuno, MD;
Toru Furukawa, MD
Arch Surg. 1999;134:1131-1136.
Hypothesis Intraductal papillary mucinous tumors (IPMTs) of the pancreas may be meaningfully construed as representing 2 clinically distinct subtypes: main duct tumors (MDT) and branch duct tumors (BDT).
Design Retrospective study.
Setting University hospital from January 1988 through December 1994.
Patients and Intervention We reviewed diagnostic findings and late results of surgical treatment in 30 patients with IPMT.
Results The tumor was located in the head of the pancreas more often in BDT than in MDT (65% [11/17] and 23% [3/13], respectively). Of the 13 patients with MDTs, 12 (92%) had intraductal papillary adenocarcinoma (noninvasive and minimally invasive types) and/or carcinoma in situ (carcinoma in situ: low papillary and/or flat tumor cells), and 3 (23%) had stromal invasion. Of the 17 patients with BDTs, 5 (29%) had intraductal papillary adenocarcinoma and/or carcinoma in situ. Two pancreatoduodenectomies and 8 pylorus-preserving pancreatoduodenectomies were performed in 10 of the 17 patients with BDTs, distal pancreatectomy in 7 patients with MDTs, and total pancreatectomy in 4 patients with MDTs. The 5-year survival rates were 47% for MDT and 90% for BDT. Four of 6 patients with MDTs who died had local recurrence. One patient died of liver metastasis and 1 of esophageal cancer. Only 1 patient with BDT of the 2 who died had recurrent disease.
Conclusions Intraductal papillary mucinous tumors may be composed of 2 clinically distinct subtypes: MDTs and BDTs. Initially, although distal pancreatectomy can be recommended for most MDTs, the need for cancer-free margins in this more aggressive type may necessitate total pancreatectomy. Pylorus-perserving pancreatoduodenectomies is recommended for most BDTs, but, because these tumors are more often adenomas, a good prognosis can be expected.
From the First Department of Surgery (Drs Kobari, Egawa, Shibuya, Shimamura, Sunamura, Takeda, and Matsuno) and the Department of Molecular Pathology (Dr Furukawa), Tohoku University School of Medicine, Sendai, Japan.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Intraductal Papillary Mucinous Neoplasm of the Pancreas: Assessment of the Likelihood of Invasiveness with Multisection CT
Ogawa et al.
Radiology 2008;0:2482071578.
ABSTRACT
| FULL TEXT
Intraductal papillary mucinous neoplasms (IPMNs): is it time to (sometimes) spare the knife?
Bassi et al.
Gut 2008;57:287-289.
FULL TEXT
Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results
Tanno et al.
Gut 2008;57:339-343.
ABSTRACT
| FULL TEXT
Surgical Outcome of Intraductal Papillary Mucinous Neoplasms of the Pancreas
Nakagohri et al.
Ann. Surg. Oncol. 2007;14:3174-3180.
ABSTRACT
| FULL TEXT
Malignant Intraductal Papillary Mucinous Neoplasm of the Pancreas: In Situ versus Invasive Carcinoma Surgical Resectability
Vullierme et al.
Radiology 2007;245:483-490.
ABSTRACT
| FULL TEXT
Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate?
Salvia et al.
Gut 2007;56:1086-1090.
ABSTRACT
| FULL TEXT
Surgical Outcomes of Noninvasive and Minimally Invasive Intraductal Papillary-Mucinous Neoplasms of the Pancreas
Takahashi et al.
Ann. Surg. Oncol. 2006;13:955-960.
ABSTRACT
| FULL TEXT
High Incidence of Extrapancreatic Neoplasms in Patients With Intraductal Papillary Mucinous Neoplasms
Choi et al.
Arch Surg 2006;141:51-56.
ABSTRACT
| FULL TEXT
Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Plea for Prospective Differentiation Between Main-Duct and Side-Branch Tumors
Castillo
Ann. Surg. Oncol. 2005;12:98-99.
FULL TEXT
Multicenter Analysis of Clinicopathologic Features of Intraductal Papillary Mucinous Tumor of the Pancreas: Is It Possible to Predict the Malignancy Before Surgery?
Jang et al.
Ann. Surg. Oncol. 2005;12:124-132.
ABSTRACT
| FULL TEXT
Clinicopathological Features of Malignant Intraductal Papillary Mucinous Tumors of the Pancreas: The Differential Diagnosis From Benign Entities
Kawai et al.
Arch Surg 2004;139:188-192.
ABSTRACT
| FULL TEXT
Spectrum of Cystic Neoplasms of the Pancreas and Their Surgical Management
Sheehan et al.
Arch Surg 2003;138:657-662.
ABSTRACT
| FULL TEXT
Characterisation of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma
Yeh et al.
Gut 2002;51:712-716.
ABSTRACT
| FULL TEXT
Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma
Maire et al.
Gut 2002;51:717-722.
ABSTRACT
| FULL TEXT
Intraductal Papillary-Mucinous Tumors of the Pancreas: Predictive Criteria of Malignancy According to Pathological Examination of 53 Cases
Bernard et al.
Arch Surg 2002;137:1274-1278.
ABSTRACT
| FULL TEXT
Aberrant p16INK4A and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma
Biankin et al.
Gut 2002;50:861-868.
ABSTRACT
| FULL TEXT
|
